Category: Home

Key Takeaways

1. Lindsey and Tim Pierce welcomed a baby boy from an embryo frozen since 1994, setting a world record for the longest frozen embryo leading to a live birth.
2. The couple faced infertility challenges and adopted the nearly three-decade-old embryo from donor Linda Archerd, who had initially created multiple embryos in 1994.
3. Out of three embryos given to the Pierces, one did not survive thawing, but two were transferred, leading to one successful implantation and birth.
4. The event highlights the effectiveness of long-term embryo storage, with approximately 1.5 million frozen embryos stored in the U.S.
5. The article also discusses a startup, Tomorrow Bio, exploring cryopreservation for deceased individuals, though human cryonics remains theoretical and controversial.

An Ohio couple, Lindsey and Tim Pierce, have just welcomed a baby boy who was born from an embryo that had been frozen since 1994. This remarkable event has set a new world record for the longest time an embryo has been frozen before leading to a live birth.

Journey to Parenthood

The Pierces faced challenges with infertility and chose to adopt an embryo, which led them to receive this nearly three-decade-old embryo. The donor, Linda Archerd, who is now 62 years old, created multiple embryos through in vitro fertilization back in 1994. Initially, she made four embryos intending to use them all; however, she ended up using only one during her marriage before her divorce. Faced with increasing storage fees and a decision against destroying the embryos, she decided to donate them instead.

A Historic Birth

From the three embryos given to the Pierces by Archerd, one unfortunately did not survive the thawing process, but two were successfully transferred into Lindsey’s uterus. Out of those, only one managed to implant and develop. This successful birth underlines the growing effectiveness of long-term embryo storage, especially considering that there are about 1.5 million frozen embryos stored across the United States.

Exploring New Frontiers

Long-term preservation of biological material is also being explored in a more controversial area. A startup named Tomorrow Bio is working on cryopreservation for deceased individuals, with the hope that future medical advancements might allow for their revival. This process involves cooling the body and substituting all water with a cryoprotective fluid to avert damage from ice crystals, before freezing it at a chilling −384.8 °F (−196 °C).

In contrast to embryo storage, human cryonics is still a theoretical concept. Critics like neuroscientist Professor Clive Coen have called the idea “preposterous,” noting that no one has been successfully brought back to life from such a state.

Source:
Link

Key Takeaways

1. 4D-150 showed significant efficacy in treating DME, with a 9.7 letter improvement in best corrected visual acuity and a 174 micrometer reduction in central subfield thickness after 60 weeks.

2. Patients receiving the Phase 3 dose of 4D-150 needed 78% fewer supplementary injections compared to those on standard aflibercept treatment.

3. Four out of nine patients in the Phase 3 group were able to go without any injections, highlighting the therapy’s potential for reduced treatment burden.

4. 4D-150 was well tolerated with no signs of intraocular inflammation or other serious complications reported during the trial.

5. The therapy has the potential to transform DME treatment by improving adherence and providing lasting vision improvements.

4D Molecular Therapeutics (4DMT) has recently shared data from a clinical trial that lasted 60 weeks, focusing on its gene therapy known as 4D-150. This innovative therapy encodes aflibercept and a sequence that inhibits vascular endothelial growth factor C (VEGF-C). The active control in this study was aflibercept, which is an anti-VEGF medication.

Positive Efficacy Results

The findings demonstrate the effectiveness of 4D-150 in treating DME. Participants who got the Phase 3 dosage of 4D-150 experienced an improvement of 9.7 letters in best corrected visual acuity (BCVA) and a 174 micrometer decrease in central subfield thickness (CST). These outcomes suggest both visual and anatomical enhancements.

Reduced Injection Needs

Patients who received the Phase 3 dose of 4D-150 after three loading doses of aflibercept needed 78% fewer supplementary injections than those following the standard 2-milligram aflibercept treatment every 8 weeks. When comparing those on lower doses of 4D-150, patients on the Phase 3 dose fared better, needing 58% fewer supplemental injections. Out of nine patients in the Phase 3 group, four were able to go without injections, while only one out of 11 in the lower dose group achieved similar results.

These findings were presented by David Almeida during the 43rd Annual American Society of Retina Specialists (ASRS) Scientific Meeting.

Transformative Potential

According to David Almeida, “4D-150 has the potential to fundamentally transform the treatment of DME by reducing treatment burden with a product that has adherence by design, while providing meaningful, lasting vision improvement.”

The 4D-150 therapy was generally well accepted by the study participants. Throughout the trial, there were no signs of intraocular inflammation at any point, and none of the subjects required any changes to their topical corticosteroid treatment. There were no reports of hypotony, endophthalmitis, vasculitis, choroidal effusions, or retinal artery occlusion. Additionally, the average intraocular pressure stayed within normal ranges.

Source:
Link

Key Takeaways

1. Quick Energy Response: Cancer cells rapidly move their mitochondria toward the nucleus under mechanical compression, forming nucleus-associated mitochondria (NAMs) that provide an immediate energy boost.

2. ATP Surge for DNA Repair: The ATP levels increase by about 60% within three seconds, which is crucial for repairing DNA damage caused by compression, allowing cells to divide properly.

3. Cytoskeletal Scaffold Importance: The process relies on the cytoskeletal scaffold, specifically actin filaments, to maintain cell shape and support the formation of NAMs; disrupting this structure halts ATP production.

4. Biopsy Findings: Analysis of breast tumor biopsies shows NAMs are three times more common at the invasive edges of tumors, suggesting a link between NAMs and cancer cell invasiveness.

5. Potential Therapy Target: Targeting the internal support structures of cancer cells may reduce their ability to respond to mechanical stress, offering a new direction for cancer treatment.

As of July 30, scientists at the Centre for Genomic Regulation (CRG) in Barcelona have discoverd a quick energy response mechanism in cancer cells when they face mechanical compression. The research indicates that when cancer cells are squeezed, their mitochondria—structures responsible for energy production—swiftly move toward the nucleus, creating clusters known as nucleus-associated mitochondria (NAMs). These NAMs provide a burst of adenosine triphosphate (ATP), which is the main energy molecule for cells, directly into the nucleus in just a few seconds.

ATP Surge and DNA Repair

The influx of ATP increases by about 60% within three seconds and is crucial for repairing DNA. When under compression, cells encounter DNA stress, leading to broken strands. The rise in ATP activates the DNA repair machinery effectively. Cells that lack this ATP surge struggle to divide properly.

Role of Cytoskeletal Scaffold

This process heavily relies on the cytoskeletal scaffold, which is an internal structure made up of actin filaments that help maintain the shape of the cell. The endoplasmic reticulum, a cell’s internal network, also plays a vital role in keeping the mitochondria close to the nucleus. Disrupting this scaffold with latrunculin A stops the formation of NAMs and halts the ATP surge. For context, latrunculin A is a chemical that breaks down actin filaments.

Insights from Patient Biopsies

An analysis of breast tumor biopsies from 17 patients revealed that NAMs were three times more prevalent at the invasive fronts of tumors—areas where cancer cells are spreading—compared to the dense tumor core. Researchers suggest that targeting this internal support structure might hinder cancer cells’ ability to respond to mechanical stress, potentially reducing tumor invasiveness while preserving healthy tissue.

The study utilized a microscope capable of compressing cells to a width of three microns. The phenomenon was seen in 84% of squeezed HeLa cells (a line of human cancer cells derived from a cervical tumor in 1951, known for their ability to grow and divide indefinitely in lab conditions) and was not present in uncompressed cells. All of this provides new insights into how cancer cells can endure mechanical challenges during invasion and, hopefully, will aid researchers in discovering a new target for therapy.

Source:
Link